Polypharmacy in three different spontaneous adverse drug event databases

Mabuchi, Takayuki; Hosomi, Kouichi; Yokoyama, S.; Takada, Mitsutaka

doi:10.5414/cp203798

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study indicated that the mean number of drugs used by PD patients was 3.8. The mean number for those aged 70 to 79 was 4.7 drugs 26 . Our results exceeded the numbers reported in this previous report.…”

Section: Discussionmentioning

confidence: 96%

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Asano,

Tian,

Hatabu

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson’s disease (PD). Selegiline, rasagiline, and safinamide are widely used as MAO-B inhibitors worldwide. Although these drugs inhibit MAO-B, there are pharmacological and chemical differences, such as the inhibitory activity, the non-dopaminergic properties in safinamide, and the amphetamine-like structure in selegiline. MAO-B inhibitors may differ in adverse events (AEs). However, differences in actual practical clinics are not fully investigated. A retrospective study was conducted using FAERS, the largest database of spontaneous adverse events. AE signals for MAO-B inhibitors, including selegiline, rasagiline, and safinamide, were detected using the reporting odds ratio method and compared. Hypocomplementemia, hepatic cyst, hepatic function abnormal, liver disorder and cholangitis were detected for selegiline as drug-specific signals. The amphetamine effect was not confirmed for any of the three MAO-B inhibitors. The tyramine reaction was detected as an AE signal only for rasagiline. Moreover, the REM sleep behavior disorder was not detected as an AE signal for safinamide, suggesting that non-dopaminergic effects might be beneficial. Considering the differences in AEs for MAO-B inhibitors will assist with the appropriate PD medication.

show abstract

Section: Discussionmentioning

confidence: 96%

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Asano,

Tian,

Hatabu

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Second, since the FAERS only contains cases with AEs, it unable to provide the total number of patients receiving BCR-ABL1 TKIs treatment. Therefore, the incidence rate of AEs associated with each drug cannot be estimated [33]. Third, because the FAERS is a self-reporting reporting system, the causal relationship between AEs and drugs may not be determined [34].…”

Section: Discussionmentioning

confidence: 99%

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting System

Zhao

Long

Wang

2023

Preprint

View full text Add to dashboard Cite

Background With the increased use of BCR-ABL1 tyrosine kinase inhibitors (TKIs) in cancer patients, adverse events (AEs) have garnered considerable interest. We conducted this pharmacovigilance study by using the Food and Drug Administration Adverse Event Reporting System (FAERS) database to evaluated the AEs of BCR-ABL1 TKIs in cancer patients. Methods We used OpenVigil 2.1 to query AE reports from the FAERS database. Descriptive analysis was used to describe the characteristics of TKIs-associated AE reports. Disproportionality analysis was used to detect safety signals by calculating proportional reporting ratio (PRR) and reporting odds ratios (ROR). Results A total of 85989 AE reports were retrieved from the FAERS database and 3080 significant AE signals were identified. The numbers of significant AE signals for imatinib, nilotinib, dasatinib, bosutinib, and ponatinib were 1058, 813, 232, 186, and 791 respectively. The significant signals were divided into 26 system organ classes (SOCs). The AE signals of imatinib and ponatinib were mainly fixed on general disorders and administration site conditions, while the AE signals of nilotinib, dasatinib, and bosutinib were mainly fixed on investigations, respiratory, thoracic and mediastinal disorders, and gastrointestinal disorders, respectively. Of note, 245, 278, 47, 55, 253 unexpected signals were observed in imatinib, nilotinib, dasatinib, bosutinib and ponatinib, respectively. Conclusions The results of the present study are compatible with clinical experience. The study showed that AE signals were differ among the five BCR‐ABL1 TKIs. Moreover, several unexpected signals were observed in each BCR‐ABL1 TKI. These findings provide valuable information for clinicians to reduce the risk of adverse drug reactions during the BCR‐ABL1 TKIs treatment.

show abstract

“…Hashimoto et al reported an association between polypharmacy and the use of medications that cause lower urinary tract symptoms (LUTS), suggesting that polypharmacy exacerbates LUTS. 1) The number of concomitant medications used in drug therapy in Japan is larger than that in other countries, 2) and eliminating multiple drug use is subject to evaluation in terms of reimbursement. Kojima et al previously reported an increased incidence of adverse drug events, including falls, in hospitalized patients taking six or more drugs.…”

Section: Introductionmentioning

confidence: 99%

Impact of Polypharmacy and Risk Factors for Exacerbation of Lower Urinary Tract Symptoms in Patients with Urological Conditions: A Retrospective Study in a Japanese Municipal Hospital

Yoshizawa,

Tachi,

Takahashi

et al. 2024

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Polypharmacy exacerbates lower urinary tract symptoms (LUTS). Japan exhibits a higher prevalence of concomitant medication use in drug therapy than other countries. Previous age-and sex-specific reports exist; however, none include patients of all ages. Therefore, this retrospective study determined the impact of polypharmacy and its associated risk factors on LUTS exacerbation in outpatients with urological conditions. We included patients receiving medication who visited the Department of Urology at the Gifu Municipal Hospital (Gifu, Japan) between January, 2018 and December, 2018. The association between LUTS and polypharmacy and the risk factors for LUTS exacerbation were investigated. Patients were categorized into two groups according to their polypharmacy status. We performed propensity score matching and compared the International Prostate Symptom Score (IPSS) between the groups using the unpaired t-test. Multiple logistic regression analysis was performed to examine the risk factors, including "polypharmacy" and "taking multiple anticholinergic medications" for LUTS exacerbation. When comparing the IPSS between the groups, the polypharmacy group was found to have significantly higher scores than the non-polypharmacy group in six items, including "total score" and "storage score." Multiple logistic regression analysis results showed high significance in three items, including "polypharmacy" (odds ratio (OR) 1.67, 95% confidence interval (CI): 1.03-2.71) and "taking multiple anticholinergic medications" (OR 8.68, 95% CI: 1.05-71.7). In conclusion, this study revealed that "polypharmacy" and "taking multiple anticholinergic medications" were risk factors for LUTS. Particularly, "polypharmacy" is associated with storage symptom exacerbation. Therefore, eliminating "polypharmacy" and "taking multiple anticholinergic medications" is expected to improve LUTS.

show abstract

Polypharmacy in three different spontaneous adverse drug event databases

Cited by 4 publications

References 0 publications

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting System

Impact of Polypharmacy and Risk Factors for Exacerbation of Lower Urinary Tract Symptoms in Patients with Urological Conditions: A Retrospective Study in a Japanese Municipal Hospital

Contact Info

Product

Resources

About